Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis

Martín‐Llahí, Marta; Guevara, Mónica; Torre, Aldo; Fagundes, Cláudia; Restuccia, Tea; Gilabert, Rosa; Solà, Elsa; Pereira, Gustavo; Marinelli, M.; Pavesi, Marco; Fernández, Javier; Rodés, Juan; Arroyo, Vicente; Ginès, Pere

doi:10.1053/j.gastro.2010.07.043

Cited by 320 publications

(287 citation statements)

References 26 publications

(61 reference statements)

Supporting

Mentioning

253

Contrasting

Unclassified

Order By: Relevance

“…In a large series of hospitalized patients with cirrhosis and kidney failure, only 5% of patients had type 2 HRS which represented an incidence of 3.5 patients/ year. 24 In other studies, incidence ranges from 3.5 to 7 patients/year. 6,[24][25][26] The relatively low frequency of type 2 HRS in our patient population is in keeping with data from these previous reports.…”

Section: Discussionmentioning

confidence: 90%

“…24 In other studies, incidence ranges from 3.5 to 7 patients/year. 6,[24][25][26] The relatively low frequency of type 2 HRS in our patient population is in keeping with data from these previous reports. There are several studies indicating that treatment with vasoconstrictors, either terlipressin or noradrenaline, together with IV albumin improves kidney function in patients with type 2 HRS.…”

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes

et al. 2015

Self Cite

View full text Add to dashboard Cite

There is little information on the effects of treatment with vasoconstrictors plus albumin in patients with type 2 hepatorenal syndrome (HRS), particularly those awaiting liver transplantation (LT). This study reports the effects of treatment of type 2 HRS in patients on the waiting list for LT. We included 56 patients with type 2 HRS who were awaiting LT. Out of these 56 patients, 31 were treated with terlipressin and albumin. Nineteen (61%) of these 31 patients had response to therapy, and 11 of them relapsed after treatment withdrawal. There were no differences in mortality on the waiting list between responders and nonresponders. Among the 46 (82%) patients who underwent transplantation, 15 underwent transplantation with reversal of type 2 HRS, whereas the remaining 31 underwent transplantation with type 2 HRS. There were no significant differences in serum creatinine or estimated glomerular filtration rate between the 2 cohorts of patients at 3, 6, and 12 months after transplantation. There were no significant differences regarding development of acute kidney injury, need for renal replacement therapy, frequency of chronic kidney disease 1 year after transplant, length of hospitalization, and survival. In conclusion, treatment of patients with type 2 HRS with terlipressin and albumin does not appear to have beneficial effects either in pretransplantation or in posttransplantation outcomes.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 90%

Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…In patients with decompensated cirrhosis, the main abnormality causing renal dysfunction is systemic and splanchnic vasodilatation secondary to portal (or sinusoidal) hypertension that leads to decreased effective arterial blood volume and activation of neurohormonal systems, the rennin-angiotensin aldosterone (RAAS), the sympathetic nervous system, and non-osmotic release of antidiuretic hormone, resulting in sodium and water retention [76][77][78]. Eventhough the systemic hemodynamic alterations in ACLF are similar to patients with decompensated cirrhotics [79], the pathogenesis of renal dysfunction in ACLF is quite different in these patients as a major role is played by SIRS and subsequent sepsis [80].…”

Section: Renal Failurementioning

confidence: 99%

Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014

et al. 2014

View full text Add to dashboard Cite

The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set up in 2004 on acute-on-chronic liver failure (ACLF) was published in 2009. Due to the rapid advancements in the knowledge and available information, a consortium of members from countries across Asia Pacific, ''APASL ACLF Research Consortium (AARC),'' was formed in 2012. A large cohort of retrospective and prospective data of ACLF patients was collated and followed up in this data base. The current ACLF definition was reassessed based on the new AARC data base. These initiatives were concluded on a 2-day meeting in February 2014 at New Delhi and led to the development of the final AARC consensus. Only those statements which were based on the evidence and were unanimously recommended were accepted. These statements were circulated again to all the experts and subsequently presented at the annual conference of the APASL at Brisbane, on March 14, 2014. The suggestions from the delegates were analyzed by the expert panel, and the modifications in the consensus were made. The final consensus and guidelines document was prepared. After detailed deliberations and data analysis, the

show abstract

“…1). 35 Bacterial infection was the most frequent precipitant followed by hypovolemia. Other etiologies included HRS and parenchymal nephropathy.…”

Section: Renal Failurementioning

confidence: 99%

Keeping high model for end‐stage liver disease score liver transplantation candidates alive

et al. 2015

View full text Add to dashboard Cite

show abstract

Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis

Cited by 320 publications

References 26 publications

Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes

Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes

Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014

Keeping high model for end‐stage liver disease score liver transplantation candidates alive

Contact Info

Product

Resources

About